Please assess the completion status of the following clinical trial:

Trial Title: Pathophysiological Study of Characteristics of the Changes in the Cutaneous Immune System After Intradermal Antigen Injections

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Both genders eligible for study.~* Female participants must use a contraceptive method.~* Tuberculin skin test between 1 and 15mm~* Participants must be able to understand and sign the Informed Consent, and comply with all aspects of the protocol.~* Subjects registered in a social security system or with health insurance cover~* First group: Healthy subjects aged from 18 to 75 years with 2 subgroups: 18-40 and 60-75 year old subjects~* Second group: Patients with kidney transplants of longer than 6 months on immunosuppressive treatment~Exclusion Criteria:~* Pregnant or lactating women.~* Previous allergic reaction to tuberculin skin test~* Active skin disease on testing zone~* Patients with a clinically significant disease (chronic, recurrent or active)~* Local or systemic medication which interacts with the outcome measures.~* Patients deprived of their civic rights, in custody, or under the care of a tutorial, judiciary or administrative body.~* Patients relevant of a protection measure~* Patients in a critical medical situation~* Patients with a personal situation evaluated by the investigator as unable to give an optimal participation in the study, or where it could constitute a risk for the patient~* Linguistic barrier or psychological profile disabling the patient from signing the consent form~* Patient still in an exclusion period following participation in another clinical trial~* Patients having earned more than 4500€ in indemnities following participation in clinical trials during the last 12 months, including this study~For group 1 only:~* Systemic corticotherapy or immunosuppressive treatment within the 2 weeks before first visit or within 2 weeks before the third visit or the biopsies.~* Systemic non anti-inflammatory drugs the week before the first visit or within 1 week before the third visit or the biopsies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).